Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.
You successfully added item(s) to your cart
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
Superhance™ 680 is a small molecule fluorescent in vivo blood pool imaging agent. Superhance 680 fluorescent imaging agent enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions. This agent binds to albumin in blood for extended (30m-1h) circulation.
|Fluorescent Agent Type||Vascular|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||Superhance|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Vascular disease, Angiogenesis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.
Superhance 680 is a small molecule fluorescent in vivo blood pool imaging agent. Superhance 680 enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions.